ХС243
/ Pharmenterprises
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 18, 2023
Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Doses of XC243 After Single and Multiple Oral Administration in Healthy Volunteers.
(clinicaltrials.gov)
- P1 | N=38 | Completed | Sponsor: PHARMENTERPRISES LLC | Recruiting ➔ Completed | Trial completion date: May 2023 ➔ Sep 2023 | Trial primary completion date: May 2023 ➔ Sep 2023
Trial completion • Trial completion date • Trial primary completion date
November 28, 2022
Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Doses of XC243 After Single and Multiple Oral Administration in Healthy Volunteers.
(clinicaltrials.gov)
- P1 | N=38 | Recruiting | Sponsor: PHARMENTERPRISES LLC
New P1 trial
1 to 2
Of
2
Go to page
1